Interestingly, Best and colleagues showed that murine models of lung adenocarcinoma harboring KRAS and LKB1 mutations exhibit increased glutaminase expression by tumor cells and increased glutamate in the tumor microenvironment, compared to KRAS mutant/KEAP1 mutant lung adenocarcinomas. This evidence concerns the gene KRAS and neoplasm.